Table 5.
Information of the real-world validation dataset.
| Amoxicillin | Ceftazidime | Cefotaxime | Meropenem | Latamoxef | |
|---|---|---|---|---|---|
| Patient (samples) | 157 (157) | 138 (138) | 104 (104) | 83 (83) | 139 (139) |
| GA (weeks)a | 38.0 (28.1–41.3) | 37.9 (26.0–43.4) | 32.0 (23.0–42.0) | 35.3 (26.3–42.1) | 37 (27.3–41.1) |
| PMA (weeks)a | 38.9 (28.4–44.1) | 40.0 (26.1–47.4) | 34.2 (26.4–44.4) | 37.1 (25.6–48.0) | 38.3 (31.0–44.1) |
| PNA (days)a | 7.0 (1.0–37.0) | 13.0 (1.0–81.0) | 8.5 (1.0–108.0) | 23.0 (4.0–116.0) | 7.0 (1.0–54.0) |
| BW (kg)a | 3.0 (1.2–4.2) | 2.8 (0.7–4.7) | 2.7 (1.4–3.5) | 1.9 (0.5–3.9) | 2.7 (1.2–4.1) |
| CW (kg)a | 3.2 (1.2–4.3) | 2.9 (0.9–4.8) | 1.9 (0.5–4.2) | 2.1 (1.1–5.3) | 2.7 (1.1–4.2) |
| CREA (μmol/L)a | 36.0 (8.8–167.9) | 34.4 (8.0–201.0) | 45.0 (12.0–226.0) | 25.2 (1.3–126.0) | 41.0 (4.5–103.0) |
| ALB (g/L)a | / | / | / | 2.3 (1.5–4.5) | / |
| Treatment | |||||
| Dose (mg/dose)a | 75.0 (25.0–110.0) | 90.0 (30.0–140.0) | 100 (28.0–208.0) | 55.0 (18.0–150.0) | 85.0 (40.0–140.0) |
| Dose (mg/kg/dose)a | 23.7 (16.7–32.1) | 29.1 (21.2–80.0) | 49.5 (31.7–105.0) | 19.8 (8.80–85.7) | 30.0 (24.0–56.1) |
| FREb | Q12h: 63.7% Q8h: 36.3% |
Q12h: 60.1% Q8h: 39.9% |
Q12h: 52.9% Q8h: 47.1% |
Q12h: 28.9% Q8h: 71.1% |
Q12h: 69.8% Q8h: 30.2% |
| FTb | 1: 13.4% 2: 8.9% 3: 77.7% |
1: 58.7% 2: 3.6% 3: 37.7% |
1: 40.4% 2: 30.8% 3: 28.8% |
1: 47.0% 2: 19.3% 3: 33.7% |
1: 15.2% 2: 46.0% 3: 38.8% |
| TARb | 0: 73.2% 1: 26.8% |
0: 41.3% 1: 58.7% |
0: 20.2% 1: 79.8% |
0: 37.3% 1: 62.7% |
0: 31.7% 1: 68.3% |
CW: current weight; BW: birth weight; GA: gestational age; PNA: postnatal age; PMA: postmenstrual age; CREA: serum creatinine; ALB: albumin; FRE: Dosage Frequency; FT: PD targets, 50/70/100% fT > MIC, 1,2,3 represent 50%, 70% and 100% respectively; TAR: prediction target, concentration meets the standard as 1, does not meet the standard as 0.
a
The results were shown in median (range).
b
The results are presented as proportions for each category.